Genistein: a soy isoflavone revealing a pleiotropic mechanism of action – clinical implications in the treatment and prevention of cancer

COMMENTARY ON THE LAW

Genistein: a soy isoflavone revealing a pleiotropic mechanism of action – clinical implications in the treatment and prevention of cancer

Adam Opolski 1 , Grzegorz Grynkiewicz 2 , Joanna Wietrzyk 1 , Czesław Radzikowski 3

1. Department of Tumor Immunology, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland
2. Pharmaceutical Research Institute Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland
3. Zakład Immunologii Nowotworów, Instytutu Immunologii i Terapii Doświadczalnej im. L. Hirszfelda, PAN we Wrocławiu

Published: 2004-03-09
GICID: 01.3001.0000.3582
Available language versions: en pl
Issue: Postepy Hig Med Dosw 2004; 58 (0)

 

Abstract

Genistein, a naturally occurring isoflavonoid, displays antitumor, antimetastatic and antiangiogenic properties, described in various experimental in vitro and in vivo models. The results of several epidemiological studies suggest that soybean consumption may contribute to lower incidence of breast, colon, prostate, thyroid, and head and neck cancers. This protective effect of soy consumption is attributed, among others, to genistein. On the other hand, genistein may enhance the proliferation of some estrogen-positive human breast cancer cells in vivo and the growth of mammary gland and mammary cancer cells in athymic mice. In this paper, various aspects of the diverse biological activities of genistein and their potential clinical implications, especially in the treatment and prevention of cancer, are reviewed and discussed.

Full text

Skip to content